Imipenem/Cilastatin Sun

Imipenem, the active ingredient in Imipenem/Cilastatin Sun, is a carbapenem antibiotic presented as an intravenous injection for systemic administration. Combined with cilastatin to inhibit renal dehydropeptidase I, it provides broad‑spectrum coverage against Gram‑negative and Gram‑positive bacteria, and is used to treat serious infections in hospitalized adults and children. The drug is indicated for intra‑abdominal, urinary tract, pulmonary, skin and soft‑tissue infections, as well as septicemia, when alternative agents are unsuitable.

GNH USA supplies Imipenem/Cilastatin Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide.

Imipenem/Cilastatin is a carbapenem antibiotic used for serious bacterial infections affecting various organ systems. Complicated intra‑abdominal infections: effective bacterial eradication leading to clinical cure. Complicated urinary tract infections: rapid clearance of uropathogens and symptom resolution. Nosocomial pneumonia: broad‑spectrum activity that improves pulmonary infection outcomes. Skin and soft tissue infections: eradicates mixed flora to promote wound healing. Septicemia: systemic bacterial clearance to stabilize hemodynamics.

Adverse reactions may occur with any antimicrobial therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be self‑limiting or indicate colitis. - Headache: transient and usually resolves. - Rash: mild skin erythema or pruritus. - Elevated liver enzymes: transient hepatic enzyme rise. - Injection site pain: local discomfort during infusion.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: acute hypersensitivity requiring immediate intervention. - Clostridioides difficile colitis: severe diarrhea with pseudomembranous colitis. - Thrombocytopenia: marked reduction in platelet count. - Renal toxicity: worsening renal function in susceptible individuals. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Use Imipenem/Cilastatin with caution in specific clinical situations. - Renal function: adjust dose in patients with impaired renal clearance. - Seizure risk: monitor patients with a history of CNS disorders. - Allergy: avoid in individuals with known hypersensitivity to carbapenems. - Pregnancy: prescribe only when the potential benefit justifies the potential risk. - Drug interactions: review concomitant medications for possible interactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Imipenem/Cilastatin may interact with other medicines; review patient medication lists.

Major Interactions (Avoid): - Valproic acid: may reduce serum valproate levels, risking seizure breakthrough. - Cisplatin: increased risk of nephrotoxicity when combined. - Probenecid: may raise imipenem concentrations, enhancing toxicity.

Moderate Interactions (Monitor Closely): - Aminoglycosides: additive nephrotoxic potential; monitor renal function. - Loop diuretics: may increase ototoxicity risk when used together. - Anticoagulants: possible enhancement of anticoagulant effect; check coagulation parameters.